跳至主要内容
临床试验/CTRI/2018/04/013279
CTRI/2018/04/013279进行中(未招募)4 期

A study to assess the efficacy of curcumin as an immunomodulator in Rheumatoid arthritis

Dr Padmanabha Shenoy D0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Diagnosed cases of rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria
  • On conventional DMARDs for at least last six months.
  • On sustained remission based on DAS 28 (DAS 28 < 2.6) and SDAI ââ?°Â¤ 3.3 and TJC (44) < 0 and SJC (44) < 0 for more than 6 months without requirement of corticosteroids or NSAIDs.
  • Documented remission status at a minimum of two consecutive visits during last 6 months .

排除标准

  • Having other associated rheumatological diseases
  • Functional class IV
  • Abnormal liver function (defined as AST/ALT > 3 X upper normal limit ) and active hepatits/cirrhosis
  • Abnormal renal function / chronic renal failure ( S. creatinine ââ?°Â¥ 2mg/dl)
  • Those who are currently on curcumin supplements
  • Known allergic reaction to curcumin
  • Major comorbidities like severe hypertension , uncontrolled diabetes mellitus , severe respiratory or cardiovascular disease , malignancy
  • Current or past use of biologics
  • Current use of Warfarin
  • Subjects with acute episodes of cholecystitis within last few months
  • Pregnant and lactating women
  • Psychiatric or mental disorders

研究者

发起方
Dr Padmanabha Shenoy D

相似试验